Author

W. Omori

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

172. Cerebrospinal fluid p75 neurotrophin receptor ectodomain differs between Alzheimer’s disease and late-life depression: links to cognition, sleep, and anxiety

Abstract Background Differentiating late-life depression (LLD) from prodromal or early Alzheimer’s disease (AD) is clinically difficult because affective and cognitive symptoms overlap and a subset of LLD patients shows amyloid-β (Aβ) positivity, limiting the specificity of core CSF Aβ/tau biomarkers. The p75 neurotrop...

W. Omori, N. Kajitani, M. Okada-Tsuchioka et al. · International Journal of Neu... · 0 citations

Review Open access Sep 2026

205. Usefulness of clozapine as maintenance pharmacotherapy after response to acute electroconvulsive therapy in schizophrenia

Abstract Background Treatment-resistant schizophrenia (TRS)—defined as insufficient response to at least two different atypical antipsychotics—affects approximately 20–33% of individuals with schizophrenia and has been linked to dopamine D₂-receptor supersensitivity. Although clozapine is the internationally recommende...

T. Nagao, Y. Fujita, G. Sato et al. · International Journal of Neu... · 0 citations

Open access Sep 2026

Cerebrospinal Fluid p75 Neurotrophin Receptor Ectodomain Levels Across Clinically Diagnosed Alzheimer's Disease, Late‐Life Depression, and Healthy Aging: A Preliminary Cross‐Sectional Study

The p75 neurotrophin receptor ectodomain (p75NTR‐ECD) has been implicated in amyloid‐β‐related neurotoxicity, but cerebrospinal fluid (CSF) levels in late‐life depression (LLD) remain uncertain. We compared clinically diagnosed Alzheimer's disease (AD), LLD, and healthy controls (HC) and reassessed exploratory symptom...

W. Omori, N. Kajitani, M. Okada-Tsuchioka et al. · Neuropsychopharmacology Repo... · 0 citations